Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson’s Disease

Author(s): Nazrul Islam* and Shafiqur Rahman*

Volume 19, Issue 3, 2022

Published on: 05 January, 2022

Page: [260 - 265] Pages: 6

DOI: 10.2174/1567201818666210331121803

Price: $65

Abstract

The COVID-19 pandemic has caused a significant burden on public health worldwide. Currently, there are limited medications for the treatment of COVID-19 in patients with Parkinson’s disorder (PD). Several antiviral drugs and other pharmacotherapies have shown promising results and are used by various delivery methods. Among the antiviral drugs, amantadine alone was reported to provide therapeutic benefit against COVID-19 in patients with PD. Here, we propose novel strategies for pulmonary drug delivery technology of antiviral drug, amantadine. As such pulmonary delivery of this drug or in combination with the additional antiviral drugs could be a more effective strategy for the treatment of COVID-19-related complications in patients with PD. Furthermore, the important benefits and limitations of this novel delivery technology will be discussed.

Keywords: Pulmonary drug delivery, COVID-19, Parkinson’s disease, an antiviral drug, lung infections, inhaled formulations.

« Previous Next »
Graphical Abstract

[1]
Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 2020, 382(8), 727-733.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[2]
Wiersinga, W.J.; Prescott, H.C. What Is COVID-19? JAMA, 2020, 324(8), 816.
[http://dx.doi.org/10.1001/jama.2020.12984]
[3]
Wiersinga, W.J.; Rhodes, A.; Cheng, A.C.; Peacock, S.J.; Prescott, H.C.; Peacock Sharon, J.; Peacock Sharon, J.; Prescott Hallie, C.; Prescott Hallie, C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA, 2020, 324(8), 782-793.
[http://dx.doi.org/10.1001/jama.2020.12839] [PMID: 32648899]
[4]
Agostini, M.L.; Andres, E.L.; Sims, A.C.; Graham, R.L.; Sheahan, T.P.; Lu, X.; Smith, E.C.; Case, J.B.; Feng, J.Y.; Jordan, R.; Ray, A.S.; Cihlar, T.; Siege, D.; Mackman, R.L.; Clarke, M.O.; Baric, R.S.; Denison, M.R. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio, 2018, 9(2) e00221-00218/00221-e00221-00218/00215.
[5]
Gordon, C.J.; Tchesnokov, E.P.; Feng, J.Y.; Porter, D.P.; Götte, M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem., 2020, 295(15), 4773-4779.
[http://dx.doi.org/10.1074/jbc.AC120.013056] [PMID: 32094225]
[6]
Al-Tawfiq, J.A.; Al-Homoud, A.H.; Memish, Z.A. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med. Infect. Dis., 2020, 34, 101615.
[http://dx.doi.org/10.1016/j.tmaid.2020.101615] [PMID: 32145386]
[7]
Deval, J.; Jin, Z.; Chuang, Y-C.; Kao, C.C. Structure(s), function(s), and inhibition of the RNA-dependent RNA polymerase of noroviruses. Virus Res., 2017, 234, 21-33.
[http://dx.doi.org/10.1016/j.virusres.2016.12.018] [PMID: 28041960]
[8]
Westover, J.B.; Sefing, E.J.; Bailey, K.W.; Van Wettere, A.J.; Jung, K-H.; Dagley, A.; Wandersee, L.; Downs, B.; Smee, D.F.; Furuta, Y.; Bray, M.; Gowen, B.B. Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res., 2016, 126, 62-68.
[http://dx.doi.org/10.1016/j.antiviral.2015.12.006] [PMID: 26711718]
[9]
Shiraki, K.; Daikoku, T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther., 2020, 209, 107512.
[http://dx.doi.org/10.1016/j.pharmthera.2020.107512] [PMID: 32097670]
[10]
Mitha, E.; Krivan, G.; Jacobs, F.; Nagler, A.; Alrabaa, S.; Mykietiuk, A.; Kenwright, A.; Le Pogam, S.; Clinch, B.; Vareikiene, L. Safety, Resistance, and Efficacy Results from a Phase IIIb study of conventional- and double-dose oseltamivir regimens for treatment of influenza in immunocompromised patients. Infect. Dis. Ther., 2019, 8(4), 613-626.
[http://dx.doi.org/10.1007/s40121-019-00271-8] [PMID: 31667696]
[11]
Belhadi, D.; Peiffer-Smadja, N.; Yazdanpanah, Y.; Mentre, F.; Laouenan, C. A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. MedRxiv, 2020, 1-14.
[12]
Matsuzono, K.; Baba, M.; Imai, G.; Imai, H.; Matsuzono, K.; Fujimoto, S. Malignant syndrome triggered by influenza A virus infection in a patient with Parkinson’s disease with improvement after intravenous peramivir treatment. Neurol. Sci., 2019, 40(6), 1291-1294.
[http://dx.doi.org/10.1007/s10072-018-3696-4]
[13]
Kadam, R.U.; Wilson, I.A. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc. Natl. Acad. Sci. USA, 2017, 114(2), 206-214.
[http://dx.doi.org/10.1073/pnas.1617020114] [PMID: 28003465]
[14]
Ahsan, W.; Javed, S.; Bratty, M.A.; Alhazmi, H.A.; Najmi, A.; Alhazmi, H.A. Treatment of SARS-CoV-2: How far have we reached? Drug Discov. Ther., 2020, 14(2), 67-72.
[http://dx.doi.org/10.5582/ddt.2020.03008] [PMID: 32336723]
[15]
Abreu, G.E.A.; Aguilar, M.E.H.; Covarrubias, D.H.; Durán, F.R. Amantadine as a drug to mitigate the effects of COVID-19. Med. Hypotheses, 2020, 140, 109755.
[http://dx.doi.org/10.1016/j.mehy.2020.109755] [PMID: 32361100]
[16]
Araujo, R.; Aranda-Martinez, J.D.; Aranda-Abreu, G.E. Amantadine Treatment for People with COVID-19. Arch. Med. Res, 2020, 51(7), 739-740.
[http://dx.doi.org/10.1016/j.arcmed.2020.06.009] [PMID: 32571606]
[17]
Thomaston, J.L.; Polizzi, N.F.; Konstantinidi, A.; Wang, J.; Kolocouris, A.; DeGrado, W.F. Inhibitors of the M2 proton channel engage and disrupt transmembrane networks of hydrogen-bonded waters. J. Am. Chem. Soc., 2018, 140(45), 15219-15226.
[http://dx.doi.org/10.1021/jacs.8b06741] [PMID: 30165017]
[18]
Cimolai, N. Potentially repurposing adamantanes for COVID-19. J. Med. Virol., 2020, 92(6), 531-532.
[http://dx.doi.org/10.1002/jmv.25752] [PMID: 32176361]
[19]
Nguyen, J.T.; Hoopes, J.D.; Le, M.H.; Smee, D.F.; Patick, A.K.; Faix, D.J.; Blair, P.J.; de Jong, M.D.; Prichard, M.N.; Went, G.T. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant Influenza virus strains in vitro. PLoS One, 2010, 5(2), e9332.
[http://dx.doi.org/10.1371/journal.pone.0009332]
[20]
Seo, S.; Englund, J.A.; Nguyen, J.T.; Pukrittayakamee, S.; Lindegardh, N.; Tarning, J.; Tambyah, P.A.; Renaud, C.; Went, G.T.; de Jong, M.D.; Boeckh, M.J. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir. Ther., 2013, 18(3), 377-386.
[http://dx.doi.org/10.3851/IMP2475] [PMID: 23264438]
[21]
Ferini-Strambi, L.; Salsone, M. COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? J. Neurol., 2020. Ahead of Print.
[22]
Antonini, A.; Leta, V.; Teo, J.; Chaudhuri, K.R. Outcome of Parkinson’s Disease Patients Affected by COVID-19. Mov. Disord., 2020, 35(6), 905-908.
[http://dx.doi.org/10.1002/mds.28104] [PMID: 32347572]
[23]
Braak, H.; Del Tredici, K.; Rüb, U.; de Vos, R.A.; Jansen, S.E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging, 2003, 24(2), 197-211.
[http://dx.doi.org/10.1016/S0197-4580(02)00065-9] [PMID: 12498954]
[24]
Liu, K.; Chen, Y.; Lin, R.; Han, K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J. Infect., 2020, 80(6), e14-e18.
[http://dx.doi.org/10.1016/j.jinf.2020.03.005] [PMID: 32171866]
[25]
Reeve, A.; Simcox, E.; Turnbull, D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing Res. Rev., 2014, 14, 19-30.
[http://dx.doi.org/10.1016/j.arr.2014.01.004] [PMID: 24503004]
[26]
Anwar, F.; Naqvi, S.; Al-Abbasi, F.A.; Neelofar, N.; Kumar, V.; Sahoo, A.; Kamal, M.A. Targeting COVID-19 in Parkinson’s patients: Drugs repurposed. Curr. Med. Chem., 2020.
[http://dx.doi.org/10.2174/0929867327666200903115138] [PMID: 32881656]
[27]
Cheong, S.L.; Federico, S.; Spalluto, G.; Klotz, K-N.; Pastorin, G. The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy. Drug Discov. Today, 2019, 24(9), 1769-1783.
[http://dx.doi.org/10.1016/j.drudis.2019.05.003] [PMID: 31102728]
[28]
Santos-García, D.; Oreiro, M.; Pérez, P.; Fanjul, G.; Paz, G.J.M.; Feal, P.M.J.; Cores, B.C.; Valdés, A.L.; García, S.C.; Castellanos, R.M.D.M. Impact of Coronavirus Disease 2019 Pandemic on Parkinson’s Disease: A Cross-Sectional Survey of 568 Spanish Patients. Mov. Disord., 2020, 35(10), 1712-1716.
[http://dx.doi.org/10.1002/mds.28261] [PMID: 32776601]
[29]
Fazzini, E.; Fleming, J.; Fahn, S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson’s disease. Mov. Disord., 1992, 7(2), 153-158.
[http://dx.doi.org/10.1002/mds.870070210] [PMID: 1316552]
[30]
Achbani, A.; Sine, H.; Naciri, A.; Baba, M.A.; Kharbach, A.; Bouchriti, Y.; Nejmeddine, M.; Naciri, A.; Kharbach, A.; Nejmeddine, M. Can the 2019 novel coronavirus cause Parkinson’s disease? Mov. Disord., 2020, 35(7), 1102-1103.
[http://dx.doi.org/10.1002/mds.28118] [PMID: 32395864]
[31]
Lippi, A.; Domingues, R.; Setz, C.; Outeiro, T.F.; Krisko, A. SARS-CoV-2: At the crossroad between aging and neurodegeneration. Mov. Disord., 2020, 35(5), 716-720.
[http://dx.doi.org/10.1002/mds.28084] [PMID: 32291797]
[32]
Sulzer, D.; Antonini, A.; Leta, V.; Nordvig, A.; Smeyne, R.J.; Goldman, J.E.; Al-Dalahmah, O.; Zecca, L.; Sette, A.; Bubacco, L.; Meucci, O.; Moro, E.; Harms, A.S.; Xu, Y.; Fahn, S.; Ray, C.K. COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis., 2020, 6(1), 18.
[http://dx.doi.org/10.1038/s41531-020-00123-0] [PMID: 32885037]
[33]
Li, J.; Long, X.; Zhu, C.; Wang, R.; Hu, S.; Wang, T.; Li, J.; Lin, Z.; Xiong, N. Management of a Parkinson’s disease patient with severe COVID-19 pneumonia. Ther. Adv. Chronic Dis., 2020, 11, 2040622320949423.
[http://dx.doi.org/10.1177/2040622320949423] [PMID: 32850107]
[34]
Brundin, P.; Nath, A.; Beckham, J.D. Is COVID-19 a perfect storm for Parkinson's disease? Trends Neurosci., 2020, 43(12), 931-933.
[35]
Hickey, A.J. Pharmaceutical Inhalation Aerosol Technology, 2nd ed; Marcel Dekker: NY, USA, 2004.
[36]
Islam, N.; Gladki, E. Dry powder inhalers (DPIs)-a review of device reliability and innovation. Int. J. Pharm., 2008, 360(1-2), 1-11.
[http://dx.doi.org/10.1016/j.ijpharm.2008.04.044] [PMID: 18583072]
[37]
Islam, N.; Stewart, P.; Larson, I.; Hartley, P. Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures? Pharm. Res., 2004, 21(3), 492-499.
[http://dx.doi.org/10.1023/B:PHAM.0000019304.91412.18] [PMID: 15070101]
[38]
Islam, N.; Cleary, M.J. Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery-a review for multidisciplinary researchers. Med. Eng. Phys., 2012, 34(4), 409-427.
[http://dx.doi.org/10.1016/j.medengphy.2011.12.025] [PMID: 22277307]
[39]
Ni, Z.; Luo, F-m.; Wang, J-m.; Liu, T-t.; Zhang, T-x.; Yang, W.; Wang, Y-r.; Xu, Z.; Zhang, W.; Wang, S-y.; Dai, B.; Li, J.; Ge, H-q.; Liang, Z-a. Suggestion for nebulized inhalation treatment of patients with new coronavirus COVID-19 disease. Open Access (OA) Online-First Publ. Res. Pap., 2020, COVID-19, 120-124.
[40]
Patton, J.S.; Fishburn, C.S.; Weers, J.G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc., 2004, 1(4), 338-344.
[http://dx.doi.org/10.1513/pats.200409-049TA] [PMID: 16113455]
[41]
Borghardt, J.M.; Weber, B.; Staab, A.; Kunz, C.; Formella, S.; Kloft, C. Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. Br. J. Clin. Pharmacol., 2016, 81(3), 538-552.
[http://dx.doi.org/10.1111/bcp.12780] [PMID: 26348533]
[42]
Duret, C.; Merlos, R.; Wauthoz, N.; Sebti, T.; Vanderbist, F.; Amighi, K. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. Eur. J. Pharm. Biopharm., 2014, 86(1), 46-54.
[http://dx.doi.org/10.1016/j.ejpb.2013.03.005] [PMID: 23523546]
[43]
Onischuk, A.A.; Tolstikova, T.G.; Sorokina, I.V.; Zhukova, N.A.; Baklanov, A.M.; Karasev, V.V.; Borovkova, O.V.; Dultseva, G.G.; Boldyrev, V.V.; Fomin, V.M. Analgesic effect from Ibuprofen nanoparticles inhaled by male mice. J. Aerosol Med. Pulm. Drug Deliv., 2009, 22(3), 245-253.
[http://dx.doi.org/10.1089/jamp.2008.0721] [PMID: 19466908]
[44]
Bartus, R.T.; Emerich, D.; Snodgrass-Belt, P.; Fu, K.; Salzberg-Brenhouse, H.; Lafreniere, D.; Novak, L.; Lo, E-S.; Cooper, T.; Basile, A.S. A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson’s disease. J. Pharmacol. Exp. Ther., 2004, 310(2), 828-835.
[http://dx.doi.org/10.1124/jpet.103.064121] [PMID: 15039453]
[45]
Islam, N.; Ferro, V. Recent advances in chitosan-based nanoparticulate pulmonary drug delivery. Nanoscale, 2016, 8(30), 14341-14358.
[http://dx.doi.org/10.1039/C6NR03256G] [PMID: 27439116]
[46]
Islam, N.; Abbas, M.; Rahman, S. Neuropathic pain and lung delivery of nanoparticulate drugs: an emerging novel therapeutic strategy. CNS Neurol. Disord. Drug Targets, 2017, 16(3), 303-310.
[http://dx.doi.org/10.2174/1871527315666161213104417] [PMID: 27978796]
[47]
Zhou, M.; Li, Q.; Cao, L.; Liu, Y.; Zha, Y.; Xie, H.; Zeng, M.; Shi, X.; Gao, Y.; Xie, L.; Luo, M.; Zeng, Y. Re-emergence of SARS-CoV2 in a discharged COVID-19 case. J. Microbiol. Immunol. Infect., 2020, 53(3), 501-502.
[http://dx.doi.org/10.1016/j.jmii.2020.03.031] [PMID: 32303482]
[48]
Hayden, F.G.; Hall, W.J.; Douglas, R.G.Jr. Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. J. Infect. Dis., 1980, 141(5), 535-542.
[http://dx.doi.org/10.1093/infdis/141.5.535] [PMID: 7373086]
[49]
Cass, L.M.R.; Brown, J.; Pickford, M.; Fayinka, S.; Newman, S.P.; Johansson, C.J.; Bye, A. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin. Pharmacokinet., 1999, 36(Suppl. 1), 21-31.
[http://dx.doi.org/10.2165/00003088-199936001-00003] [PMID: 10429837]
[50]
Islam, N.; Rahman, S. Pulmonary drug delivery: Implication for new strategy for pharmacotherapy for neurodegenerative disorders. Drug Discov. Ther., 2008, 2(5), 264-276.
[PMID: 22504719]

Rights & Permissions Print Cite
Article Metrics
43
1
© 2024 Bentham Science Publishers | Privacy Policy